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Background: Fibromyalgia diagnosis is a challenging and long process, especially among primary care physicians
(PCPs), because of symptom heterogeneity, co-morbidities and clinical overlap with other disorders. The purpose
was to develop and validate a screening tool in French (FR), German (DE) and English (UK) to help PCPs identify
patients with fibromyalgia.
Methods: The FibroDetect questionnaire was simultaneously developed in FR, DE and UK based on information
obtained from a literature review, focus groups conducted with clinicians, and face-to-face interviews with
fibromyalgia patients (FR, DE and UK, n = 23). The resulting tool was comprehension-tested in patients with diagnosed
or suspected fibromyalgia (n = 3 and n = 2 in each country, respectively). Acceptability and applicability were assessed
and the tool modified accordingly, then assessed in clinical practice. A scoring method was created using an iterative
process based on statistical and clinical considerations with American College of Rheumatology + (ACR+) patients and
ACR– patients (n = 276), and validated with fibromyalgia and non-fibromyalgia patients (n = 312).
Results: The FibroDetect included 14 questions assessing patients’ pain and fatigue, personal history and attitudes,
symptoms and impact on lives. Six questions were retained in the final scoring, demonstrating satisfactory discriminative
power between ACR + and ACR- patients with area under the Receiver Operating Characteristic curve of 0.74. The
predictive accuracy of the tool increased to 0.86 for fibromyalgia and non-fibromyalgia patient detection, with a
sensitivity of 90% and a specificity of 67% for a cut-off of 6 on the score.
Conclusions: The FibroDetect is a self-administered tool that can be used as a screening classification surrogate to the
ACR criteria in primary care settings to help PCPs detect potential fibromyalgia patients among a population complaining
of chronic widespread pain.
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Fibromyalgia is a chronic condition associated with
widespread pain, fatigue and tender points [1,2]. A re-
cent European survey conducted in France, Germany,
Italy, Portugal and Spain estimated a prevalence ranging
from 1.4% (France) to 3.7% (Italy) [3]. The condition* Correspondence: iguillemin@mapigroup.com
3Mapi HEOR & Strategic Market Access, 27, Rue de la Villette, 69003 Lyon, France
Full list of author information is available at the end of the article
© 2014 Baron et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.affects women more commonly than men and the inci-
dence increases with age [4,5].
The American College of Rheumatology (ACR) criteria
provided guidelines for researchers to define fibromyalgia
[2] that are used extensively by doctors in everyday practice
to diagnose fibromyalgia. To be diagnosed with fibromyal-
gia, one must have experienced widespread pain for at least
3 months and have a minimum of 11 out of the 18 speci-
fied points on the body that are painful under relativelytd. This is an Open Access article distributed under the terms of the Creative
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classified ACR+); the other diseases that could mimic
fibromyalgia symptoms should be excluded [2]. More re-
cently, in an attempt to address the subjectivity in perform-
ing these tender point exams and thus simplify diagnosis in
primary and specialty care, preliminary diagnostic criteria
that eliminates the requirement for a physical or tender
point exam have been proposed by the ACR [6]. These up-
dated criteria consist of both the widespread pain index
(WPI) and the symptom severity (SS) scale that are to be
completed by the clinicians.
Despite these attempts, fibromyalgia diagnosis is chal-
lenging for several reasons, including the high heterogen-
eity of symptoms; the many co-morbidities (i.e., digestive,
psychological and cognitive dysfunction) in these patients;
and the overlap of symptoms associated with other mus-
culoskeletal, rheumatologic and psychiatric disorders, or
pain-causing conditions like neuropathic pain [1,2,7-10].
Even though clinicians’ awareness and scepticism about
fibromyalgia have favourably changed in the last years,
fibromyalgia condition is still under diagnosed.
Although the ACR criteria are widely used and sensitive,
they remain problematic for health professionals, especially
primary care physicians (PCPs) who rarely or improperly
use them [11,12] to establish a fibromyalgia diagnosis
[11,12]. In practice, PCPs are often the first health profes-
sionals fibromyalgia patients consult because of their poor
quality of life. They are recommended to use ACR criteria
in conjunction with the patients’ medical history, symp-
toms and co-morbidities, and the results of biological and
laboratory exclusion tests [13]. Consequently, patients are
likely to undergo multiple consultations before receiving a
positive diagnosis and adequate care management [14]. In-
correct diagnosis is also very frequent. Delayed or misdiag-
nosis, along with the condition itself have major impact on
patients’ emotional state and quality of life, as well as on
societal and health care costs [15,16]. Therefore, a simple
questionnaire for PCPs that is capable of translating pa-
tients’ complaints and experience into clues to potential
fibromyalgia would be highly valuable. A review of the
existing questionnaires showed that these either focus on
a specific aspect, domain or symptom of fibromyalgia
[7,17-22], or have not been adapted for use in clinical
practice [23]. The content of the Multidimensional Health
Assessment Questionnaire (MDHAQ) makes it an inter-
esting candidate; however, its complex scoring restrains its
use in clinical practice [24]. More recently, the Fibromyal-
gia Rapid Screening Tool (FiRST) and the Fibromyalgia
Diagnostic Screen have been designed to identify fibro-
myalgia in daily practice and clinical research [25,26]. Both
require further work to determine their performances in
real-life conditions by PCPs. The promising discriminative
value of the FiRST was determined based on well diag-
nosed patients (fibromyalgia versus rheumatoid arthritis,osteoarthritis and ankylosing spondylitis), and thus may not
reflect real-life, with undiagnosed patients consulting with
pain and/or fatigue complaint [26]. As for the Fibromyalgia
Diagnostic Screen, the tool lies on clinician testing, in par-
ticular the tender points [25], which could make the tool
not practical and not reliable for use by PCPs. Finally, the
completion by clinicians of the updated ACR criteria may
introduce a bias in patients’ responses, and may therefore
be not as accurate as when patients directly report and de-
scribe their experience and feeling.
To answer the need for a reliable and specific tool that
assists PCPs in screening for fibromyalgia in their day-
to-day practice, we developed the FibroDetect tool. Its de-
velopment followed a standardized methodology, which
should ensure its acceptability by the scientific community
and suitability for use in clinical practice [27]. The valid-
ation study resulted in the definition of a scoring method
and a threshold allowing for identification of potential fibro-
myalgia patients through the discrimination between ACR–
and ACR+ patients. This paper reports the process for
simultaneous development and validation of FibroDetect.
Methods
Ethics
The project was performed in accordance with Good
Clinical Practices and in compliance with local regula-
tory requirements. The appropriate national authorities
and institutional review boards approved the project be-
fore project commencement. Each patient gave informed
consent.
The study has been approved by:
– UK (pilot study): NHS National Research Ethics
Services Bournemouth and Poole; Dorset Primary
care Trust; Hampshire Community Health Care;
Stockport Research Ethics Committee.
– DE: Ethics from the study national coordinator (Ralf
Baron), i.e. ethics from Kiel Medizinische Fakultät
der Christian-Albrechts Universität zu Kiel. This
approval has been notified to the following landers:
Landesärztekammer Baden-Württemberg; Bayerischen
Landesärztekammer; Ärztekammer Hamburg; Uni
Greifswald; Ärztekammer Niedersachsen; Ärztekammer
Nordrhein; Ärztekammer Saarlandes; Sächsische
Landesärztekammer; Ärztekammer Schleswig-
Holstein), who approved.
– FR: National Commission for Data Protection and
Liberties (CNIL) and Committee for personal
protection (CPP) from Ile de France, Hôtel Dieu;
75181 Paris Cédex 04.
International Working Group
A European multidisciplinary group, representative of
the several clinical fields involved in the management of
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specialists (n = 3), rheumatologists (n = 4), a psychiatrist,
a neurologist and a pharmaco-toxicologist working in a
pain centre. It also included experts in patient question-
naire development methodology (n = 3). The experts
were involved throughout the development and valid-
ation process of the FibroDetect tool. They provided
clinical expertise and identified key issues in fibromyal-
gia detection that are seen in practice.
Development phase
Development of the conceptual model and test version of
the FibroDetect
A literature review was performed to collect information
on the symptoms, screening and diagnosis, influencing and
triggering factors that characterize fibromyalgia. In parallel,
focus groups with PCPs were conducted in France (n = 7)
and in the UK (n = 8) to explore their experience of fibro-
myalgia and to learn about their expectations and unmet
needs in their practices. Focus groups previously con-
ducted with German PCPs, pain specialists and rheumatol-
ogists completed the data.
Following the literature review and PCP interviews,
face-to-face interviews with 23 patients (n = 10 in France
and in Germany, n = 3 in the UK) were performed by psy-
chologists to explore their experiences and perceptions of
fibromyalgia, their medical history relating to fibromyalgia,
and their description of pain. Eligible patients had a recent
diagnosis of fibromyalgia (≤3 months) with widespread
pain as the main complaint.
Focus groups and interviews were performed using a
semi-structured interview guide and a non-directive tech-
nique so that participants answered questions spontan-
eously, without the bias of the interviewer intervention
[28]. Transcripts from the focus groups were analysed
using a thematic analysis approach, extracting information
related to the research question (i.e., to help PCPs identify
fibromyalgia in their practice) and organising it into con-
cepts and sub-concepts.
Factors identified from the literature review, clinicians’
focus groups and patient interviews that may help in the
detection of fibromyalgia were organised into a concep-
tual model of the concepts and sub-concepts relative to
the research question. No new concepts and information
were identified from further Belgian and Swiss interviews
(n = 6; interviews conducted in French), confirming satur-
ation of our data. The resulting conceptual model was dis-
cussed, amended and agreed upon by the experts of the
working group (see Figure 1).
Using patients’ own words, items covering each of the
concepts and sub-concepts of the final conceptual model
were generated simultaneously in French, German and
UK English, along with response choices, instructions and
layout of the screening tool. The resulting test version ofthe tool was reviewed by the international working group
to ensure its clinical relevance.
Assessing the test version of the FibroDetect
The test version was tested with another 15 patients in
France, Germany and the UK (5 patients per country).
Psychologists conducted face-to-face comprehensive test-
ing interviews. The purpose was to ensure comprehensive-
ness, clarity, cultural relevance and appropriateness of the
questionnaire for the patients. Eleven patients were diag-
nosed with fibromyalgia and 4 patients were experiencing
unexplained chronic pain but not yet diagnosed with
fibromyalgia. Cognitive interviewing methodology was
used, allowing researchers to understand the cognitive
processes involved when respondents answered questions
[28]. Based on patients’ comments, the test version was re-
vised. Upon approval from the experts, the revised test
version was harmonized among the three languages and
checked for linguistic equivalence by a linguistic expert. A
pilot version was obtained in the three languages.
Testing the pilot version of the FibroDetect in
real-life conditions
The acceptability of the tool, in terms of relevance, ease of
use and applicability by PCPs in their clinical practice, was
assessed using the PRAgmatic Content and face validity-
Test© (PRAC-Test©) [29] during a cross-sectional, observa-
tional, multicentre study conducted in the UK, Germany,
and France with PCPs. Fourteen PCPs participated in the
study, recruiting a total of 34 patients (16 in France, 15 in
Germany and 3 in the UK). Eligible PCPs had to be famil-
iar with fibromyalgia. Patient selection criteria were the
same as for the comprehension testing.
Based on comments and suggestions from PCPs, the
tool was further revised. The final revision, approved by
the experts, resulted in the version of the FibroDetect
ready for psychometric validation.
Validation phase
Study design and population
A cross-sectional, observational and multicentre study
was conducted in France and Germany. ACR 1990 criteria
were used as the gold standard for detection of fibromyal-
gia [2]. Because ACR criteria are seldom used and are
sometimes misused by PCPs, the validation study took
place in secondary care settings. Patients were recruited
by rheumatologists, pain specialists and neurologists expe-
rienced in the diagnosis and management of patients with
fibromyalgia; these were classified into one investigational
group and two control groups (see Figure 2). Patients
whose ACR were not determined (ACR-not deter-
mined) constituted the investigational group and corre-
sponded to the target population of the tool; this group
included patients with chronic widespread pain for
Figure 1 Conceptual model of factors that could help primary care physicians in the detection of fibromyalgia in practice. Model developed
based on literature review, clinicians’ focus groups and patients’ interviews. Boxes with no colour, information retrieved from patients interviews only;
boxes in light grey, information retrieved from the literature review, focus groups and patient interviews; hatched boxes, information retrieved from the
literature review only; boxes in dark grey, information retrieved from PCPs focus groups only.
Figure 2 Flow chart of the populations for the validation study. ACR, American College of Rheumatology; FM, fibromyalgia.
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visit to the specialist. Fibromyalgia and non-fibromyalgia
groups constituted the control groups. The fibromyalgia
group corresponded to patients diagnosed with fibro-
myalgia at least 6 months prior to inclusion; the non-
fibromyalgia group included patients diagnosed with a
confirmed disease for chronic widespread pain other
than fibromyalgia (localized musculoskeletal pain, com-
mon localized low back pain, osteoarthritis, inflammatory
arthritis, lupus, multiple sclerosis, peripheral neuropathy,
post-herpetic neuralgia, cancer pain, migraine/chronic ten-
sion headache, complex regional pain syndrome). Recruit-
ing physicians were asked to classify their ACR-not
determined patients as ACR + or ACR- after clinical exam-
ination and FibroDetect completion, based on the ACR
criteria and their own opinion and knowledge of the
patient.Item reduction and creation of the discriminant model for
the classification of ACR patients
The discriminant model (i.e., the combination of Fibro-
Detect items allowing separation of patients), was
created with the investigational group (ACR + and
ACR– patients). Partial least squares discriminant ana-
lysis (PLS-DA) was performed successively on different
combinations of items of the screening tool to deter-
mine the items that best separated ACR + patients
from ACR– patients and to create the FibroDetect
scoring method. PLS-DA is a multivariate classification
method that aims to associate a dependent variable
block Y (here, the ACR classification) to a covariate
block X (here, the FibroDetect items). PLS regression
combines features from principal component analysis
(PCA) and multiple regression, and is able to account
for multicollinear variables, incomplete data, and a lar-
ger number of variables in comparison to the number
of observations [30,31]. Items to be kept in the succes-
sive models were selected from an iterative process
based on 1) the percentage of missing responses to
each item; 2) the odds ratio with 95% confidence inter-
val for each individual item, evaluating its ability to
discriminate between ACR + and ACR– classifications;
3) the variable of importance (VIP) of individual items
resulting from PLS-DA, with a VIP criterion higher
than 1 generally considered of major importance in the
discriminant model [32]; 4) relevance from clinicians’
and patients’ perspectives. In addition, the ability of
each model (combination of items) to separate ACR +
from ACR– patients was evaluated using the Area
Under (AUC) the Receiver Operating Characteristic
(ROC) Curve. The higher the AUC, the better the pre-
diction; an area value of 0.5 means predictions were
not better than random guessing [33].Definition of a threshold for classification of ACR patients
Once the scoring method was created, a score threshold
was defined to optimize the classification of patients at
the individual level and ensure that a maximum number
of ACR + patients were properly classified. This should
maximize the probability for ACR + patients to be cor-
rectly classified as ACR + patients (i.e., the sensitivity)
while limiting the probability for ACR– patients to be
incorrectly classified. The score threshold was deter-
mined for the best discriminant model obtained and
was selected to correspond to a sensitivity of 95% with a
specificity (i.e., the probability for ACR– patients to be
correctly classified as ACR– patients) of at least 50%.Testing the ability of the FibroDetect to differentiate
patients with fibromyalgia from those without fibromyalgia
(non-fibromyalgia)
As part of the validation process of the FibroDetect, the
discriminant model and threshold defined with ACR +
and ACR– patients were applied to the control group
population to evaluate their ability to separate fibromyal-
gia patients from non-fibromyalgia patients.Statistical software and statistical threshold
The threshold for statistical significance was p < 0.05 for
each test. An odds ratio with a 95% confidence interval
excluding the value 1 indicated that the item was signifi-
cantly able to discriminate between groups of patients.
Statistical analyses were performed with SAS software for
Windows (Version 9.2, SAS Institute, Inc., Cary, NC, USA).
PLS-DA was performed using SIMCA Software (SIMCA-P
Version 10.0.4.0, Copyright© 1993–2002 Umetrics AB).Results
Development of the FibroDetect
Conceptual model of the factors that may aid PCPs in the
detection of potential fibromyalgia and test version of the
FibroDetect
The conceptual model, developed from the literature,
PCP and patient findings, comprised nine concepts that
were considered by the clinical experts to be factors that
could help PCPs in the detection of fibromyalgia. These
factors were: “description and definition of fibromyal-
gia,” “associated symptoms,” “co-morbidities,” “impact
on patients’ lives,” “influencing factors,” “patients’
socio-demographic characteristics,” “patients’ attitudes
and behaviours towards fibromyalgia,” “patients’ med-
ical history” and “patients’ personal history” (Figure 1).
After item generation, the test version of the screening
tool contained 14 questions, including a silhouette for
patients to indicate location of pain.
Table 1 Structure and content of the FibroDetect
screening tool (version for validation study)
COVER PAGE: to invite the appropriate patients to complete the
screening tool
• Attention-capturing sentences
INSIDE PAGE: to allow the patients to describe their pain, fatigue and
other symptoms
Question 1* • Location of the pain (body diagram to complete)
Question 2 • Frequency of the pain
Question 3 • Description of the pain
(list of sensations/perceptions)
Question 4 • Frequency of tiredness
Question 5 • Impact of physical effort on tiredness
Question 6 • Symptoms patients experienced that are associated
with their condition (list of symptoms)
INSIDE PAGE: to capture the link between patients’ condition and life,
and the impact of fibromyalgia on their everyday life, personality
and attitude
Question 7 • Impact of situations on patients’ condition (list of
physical, psychological and external situations)
Question 8 • Impact of patients’ condition on their
everyday life areas (list of life areas)
Questions 9 and 10 • Assessment of traumatic or stressful events in
patients’ life
Question 11 • Attitude and behaviour of patients faced
with their condition (list)
Question 12 • Statements about the disease
Question 13 • Extent to which patients recognise
themselves in the questions being asked
Question 14 • Content of the tool allowing report
of current health status
*To facilitate the use of and optimise the information resulting from answers
collected for the silhouette, the front and back silhouettes were divided into
16 body areas, and one item for the number of areas indicated by the patient.
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Development of the pilot version of the FibroDetect:
content validity
The test version of the FibroDetect was very well accepted
by patients. The majority of the patients found the ques-
tions and item content to be relevant and understandable
and the format of the tool appropriate. Items and response
choices that were found too confusing, overlapping, not
capturing the targeted concept appropriately or not under-
stood correctly were reformulated, reworded or reorga-
nized. One question was added that allows patients to
describe their current health status; two other questions
were combined. Upon experts’ approval, the revised ver-
sion of the screening tool was harmonized among lan-
guages and checked for linguistic equivalence. The pilot
version of the tool was named Fibromyalgia Detection
screening tool (FibroDetect), and was finalised in UK
English, French and German.
Pilot testing of the FibroDetect in real-life conditions:
face validity
Analysis of the PRAC-Test completed by the PCPs (n = 14)
supported the overall good acceptability of the screening
tool by practicing PCPs. There was a strong concordance
between the objectives of the tool and PCPs’ feedback.
They found it useful for making their decision and for im-
proving communication with their patients; they found
the information collected via the tool relevant. Six PCPs
(n = 6) suggested shortening and simplifying questions as
much as possible.
The pilot version of the tool was further revised accord-
ing to PCPs’ comments and suggestions. After a final
check for linguistic equivalence and harmonisation across
the three language versions, the FibroDetect tool was
ready for the validation study. This version was a 4-page
leaflet (11.7 inches high × 3.94 inches wide), containing 14
questions, including one silhouette. Its structure and con-
tent are described in Table 1.
Item reduction and creation of the discriminant model for
the classification of ACR patients
A total of 589 patients were recruited into the validation
study (Table 2). The classification of the study populations
is summarised in Figure 2. All 589 patients recruited by
specialists (42 specialists recruited at least 1 patient each)
completed the FibroDetect questionnaire. Among these
patients, one subject had a missing final ACR classification
and was thus not included in the investigational group.
The percentage of missing responses to the FibroDetect
items ranged from 0.0% to 14.4%. The highest percentages
of missing responses were found for items of question 11
(coping attitudes), and for items of question 7 (influencing
factors), regardless of the investigational or control group.
On average, patients had 1 missing item for each group.More than two-thirds of patients had no missing item (67%
for ACR+ patients, 66% for ACR– patients, 73% for fibro-
myalgia patients and 68% for non-fibromyalgia patients).
The discriminant model was created from an iterative
process, starting with the 14-question long original Fibro-
Detect. Discriminant models were successively tested. For
each model, the ROC curve was drawn and evaluated in
terms of ability to separate ACR + patients from ACR– pa-
tients using the AUC.
Item coding was simplified based on item distribution,
content and clinical considerations. The best performing
and simplest model found to separate ACR + from ACR–
patients included questions 1 to 6 (about physical evalu-
ation) and question 13 (about patient recognizing self in
the questions asked in the questionnaire) (Table 3). Fur-
ther PLS-DA were performed on models combining clin-
ical variables collected at the doctor visit with FibroDetect
questions or using weighted scores; this did not substan-
tially increase the ability of the model to discriminate be-
tween ACR + and ACR − patients. The FibroDetect score
Table 2 Socio-demographic and clinical characteristics of patients who participated in the validation study (N = 588)
Variable
Investigational group Two control groups
ACR + (N = 137) ACR– (N = 139) FM (N = 158) Non-FM (N = 154)
Country - N (%)
Germany 45 (32.8) 62 (44.6) 41 (25.9) 36 (23.4)
France 92 (67.2) 77 (55.4) 117 (74.1) 118 (76.6)
Age (years)
N 137 139 158 154
Mean (SD) 51.5 (11.0) 52.3 (14.0) 52.0 (11.6) 55.3 (14.6)
Median (Q1 - Q3) 52.0 (46.0 - 58.0) 52.0 (43.0 - 61.0) 53.0 (44.0 - 59.0) 55.0 (46.0 - 65.0)
Min – Max 19.0 - 87.0 19.0 - 89.0 25.0 - 87.0) 18.0 - 83.0)
Gender - N (%) Female 118 (86.1) 114 (82.0) 145 (91.8) 109 (70.8)
Time since first chronic
widespread pain (years)
N 129 137 152
-
Mean (SD) 6.1 (6.8) 5.5 (7.7) 9.9 (9.6)
Median (Q1 - Q3) 4.0 (1.0 - 9.0) 3.0 (1.0 - 5.0) 7.0 (4.0 - 13.0)
Min – Max 0.0 - 36.0 0.0 - 42.0 0.0 - 62.0
Number of doctors already visited
for pain and/or fatigue - N (%)
First doctor 7 (5.1) 6 (4.3) 4 (2.5)
-2-5 106 (77.4) 113 (81.3) 95 (60.1)
> 5 21 (15.3) 20 (14.4) 52 (32.9)
Number of tender points - N (%) < 11 18 (13.1) 124 (89.2)
- -
≥ 11 119 (86.9) 15 (10.8)
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above was calculated as the sum of the 9 item scores,
thus ranging from 0 to 9. The FibroDetect score was
calculated only if all 9 items were completed; otherwise
the score was set to missing. The AUC corresponding
to the model was of 0.74, with a sensitivity of 77% and a
specificity of 61% for a score threshold of 6 (Figure 3).
Questions 7 to 12 and question 14 of the original
FibroDetect, even though not included in the calcula-
tion of the scores, were kept within the questionnaire.
Definition of the threshold
Based on the sensitivity and specificity of the FibroDetect
score (Figure 3), three thresholds were defined: ≤ 3, 4–5,
and ≥ 6 (Table 4). According to these thresholds, less than
9% of ACR+ patients and about a quarter of ACR– pa-
tients had a score ≤ 3, 15% of ACR + patients and about
40% of ACR– patients had a score of 4 or 5, and more
than three-quarters of ACR + patients and about 40% of
ACR– patients had a score ≥ 6.
Testing the ability of the FibroDetect to differentiate
patients with fibromyalgia from those without fibromyalgia
(non-fibromyalgia)
When applied to the fibromyalgia and non-fibromyalgia
control group, the FibroDetect discriminant model (com-
posed of 6 questions) resulted in an AUC of 0.86, indicating
a good ability of the model to separate fibromyalgia from
non-fibromyalgia patients (Figure 3). According to the
thresholds defined on the FibroDetect score, 90% of fibro-
myalgia and 33% of non-fibromyalgia patients had a score ≥6, while 3% of fibromyalgia and 32% of non-fibromyalgia
patients had a score ≤ 3; 8% of fibromyalgia and 35% of
non-fibromyalgia patients had a score of 4 or 5 (Table 4).
Discussion
The FibroDetect tool was developed to meet the need of
PCPs for a specific tool to help them screen for potential
fibromyalgia patients in their routine practice. It is avail-
able in French, German and UK English and is validated
in French and German. The development phase of the
tool followed a standardised methodology [27] as well as
regulatory authorities’ recommendations, with involve-
ment of all parties who are ultimately targeted by the
tool, i.e., patients and PCPs [34,35]. Altogether, these en-
sure the credibility, robustness and acceptability of the
FibroDetect as a scientifically sound screening tool; the
involvement of a group of multidisciplinary fibromyalgia
experts throughout the work reinforces the clinical rele-
vance and appropriateness of the tool.
The validation study then allowed the finalization of
FibroDetect, and consisted in item selection and calcula-
tion of the score of the discriminant model and in the
assessment of the ability of this discriminant model to
differentiate patients with ACR + from those with ACR–.
The optimal discriminant model of FibroDetect, in terms
of simplicity of the score calculation and performances
included the questions related to the physical burden of
fibromyalgia and the question about the patient’s self-
recognition based on the information in the questionnaire.
A score ranging from 0 to 9 could be easily and quickly
computed from responses given by patients to these
A)
Figure 3 ROC curve of the final FibroDetect discriminant model; A: In
(FM + and FM-). Sensitivity: probability for ACR+ or FM+ patients to be co
ACR– or non-fibromyalgia patients to be incorrectly classified; Diagonal: AU
under the ROC curve: Area Under the Receiver Operating Characteristic cur
Table 3 Final discriminant model based on modified
FibroDetect items
Question Response choices Coding





At least one body part of upper
limb ticked (right and left arms)
Yes 1
No 0
At least one body part of lower
limb ticked (right and left legs)
Yes 1
No 0




3 At least 3 kinds of pain ticked* Yes 1
No 0




5 Impact of physical effort
on tiredness




6 At least 7 symptoms ticked** Yes 1
No 0
13 Extent to which patients
recognize themselves in
the questions being asked
Absolutely 1
A little or Not at all 0
*Among 8 kinds of pain: muscle aches, cramps, pins and needles, stabbing,
shooting pain, burning, pulling and pain that moves from one place to another.
**Among 17 symptoms: stiffness, headaches, tiredness, tiredness on waking
up, exhaustion, insomnia, disrupted or disturbed sleep, sensitive to cold or
heat, sensitive to smells, sensitive to noise, sensitive to touch, problems
remembering things, problems concentrating, nausea, diarrhoea, constipation
and problems with urination.
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likely to be ACR + patients, and should thus not be
referred to a fibromyalgia specialist; patients with a Fibro-
Detect score of 4 or 5 may require further evaluation to
decide whether they should be referred to a fibromyalgia
specialist; patients with a FibroDetect score ≥ 6 are likely
to be ACR + patients, and should thus be referred to a
fibromyalgia specialist. The AUC of the model was 0.74,
with a sensitivity of 77% and a specificity of 61% for a score
threshold of 6. At first, these values may appear limited
when compared to other tools recently developed, e.g.,
FiRST [26] or Fibromyalgia Diagnostic screen [25]. How-
ever, the FibroDetect model was created and validated with
patients for whom there was a diagnosis challenge (they
were classified as ACR+ or ACR– after inclusion and clin-
ical examination), unlike the FiRST study which used pa-
tients who already passed the difficult process of diagnosis
[12]. In this particular context, one could assume that an
AUC of 0.74 reflected very good ability to discriminate pa-
tients with no diagnosis established at inclusion but with
chronic pain and fatigue as complaint. In real life con-
texts, these symptoms characterise the patients who
consult PCPs. When applied to diagnosed fibromyalgia
and non-fibromyalgia patients, the AUC of the FibroDe-
tect tool reached 0.86, approaching the value of the
FiRST [26], with a sensitivity of 90% and a specificity of
67% for a threshold of 6, thus confirming the good predict-
ive property of the FibroDetect in cases where diagnosis is
pre-established. The design of the FibroDetect project, un-
like the FiRST, is likely to allow predictive values to be gen-
eralised to the targeted patient population.
Findings from both the qualitative phase of this pro-
ject and from literature [18,36-41] highlight theB)
vestigational group (ACR + and ACR-); B: Control groups
rrectly classified as ACR+ / FM +; 1 – Specificity: probability for
C = 0.5, i.e., predictions are not better than random guessing AUC
ve; ACR, American College of Rheumatology; FM, fibromyalgia.
Table 4 Description of FibroDetect score and thresholds
FibroDetect score
Investigational group Control group
ACR + (N = 137) ACR– (N = 139) FM (N = 158) Non-FM (N = 154)
FibroDetect score N 129 133 153 148
Mean (SD) 6.8 (1.9) 5.1 (1.9) 7.6 (1.5) 4.7 (2.1)
Median (Q1 - Q3) 7.0 (6.0 - 8.0) 5.0 (4.0 - 6.0) 8.0 (7.0 - 9.0) 5.0 (3.0 - 6.0)
Min – Max 2.0 - 9.0 1.0 - 9.0 2.0 - 9.0 0.0 - 9.0
Thresholds1 ≤ 3 - N (%) 11 (8.5) 28 (21.1) 4 (2.6) 47 (31.8)
4-5 - N (%) 19 (14.7) 53 (39.8) 12 (7.8) 52 (35.1)
≥ 6 - N (%) 99 (76.7) 52 (39.1) 137 (89.5) 49 (33.1)
1Missing data were not included in the calculation of percentages.
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clearly appears that in addition to the symptomatic pic-
ture, the detection of fibromyalgia also requires the as-
sessment of multiple factors including patients’ past
history and characteristics, impact of fibromyalgia on
patients’ daily life, and situations affecting patients’ con-
dition. Even though the corresponding questions in
FibroDetect were not found to be of primary import-
ance in the detection of fibromyalgia patients in the val-
idation study, they most certainly enable patients to
express the burden of chronic pain in terms of psycho-
logical dimensions, and provide clinicians a more
complete picture, and then a better understanding, of their
patients’ health status and complaint. They also give mean-
ing to the question included in the FibroDetect score about
the patient’s self-recognition. Finally, these questions
may be particularly useful for patients with a FibroDetect
score of 4 or 5, as they could give clinicians additional in-
formation about the patient’s feelings and help them decide
whether this patient should be referred to a fibromyalgia
specialist or not. Therefore, we suggest keeping these ques-
tions in the FibroDetect tool, even though they are not used
in the calculation of the FibroDetect score.
FibroDetect is to our knowledge the only fibromyalgia-
specific tool that comprehensively covers all domains
that are impacted by fibromyalgia as reported directly by
patients: physical aspects as well as other aspects that
characterize the condition and could be helpful detec-
tion factors (pain fatigue, patients’ personal and medical
history, patients’ personality and attitude adopted to-
wards their condition, their symptoms, and impact of
the condition on their lives). This quality is probably ex-
plained by the emphasis on patients that was made dur-
ing the development phase of the tool. Such emphasis is
missing or only partially treated in the recently designed
Fibromyalgia Diagnostic Screen and FiRST measures
[25,26]. As for the updated fibromyalgia ACR criteria [6],
patients’ perspective is not directly considered as the tool
is completed by clinicians.. In addition, the performances
of these updated criteria to diagnose fibromyalgia at earlystage in primary care settings remain to be assessed.
Should the FibroDetect be used as a diagnostic tool, a
study with a new adapted design should be conducted.
Despite its simple scoring, the length of the FibroDetect
tool may limit use in clinical practice because of time con-
straints faced by PCPs. A short version of the FibroDetect
including only the 6 fibromyalgia-physical related burden
questions and the self-recognition question used for the
scoring could be considered. However, this version would
require to be validated prior to being used in clinical prac-
tice. The validation study was conducted in France and
Germany only. Probably due to the lack of recognition of
the disease in the UK on the one hand and recruitment
difficulties on the other, validation was not possible in the
UK. Therefore, if the tool is to be used in the UK, a pre-
liminary validation in the UK population will be required.
In addition, further real life longitudinal studies would be
worthwhile to consolidate the validation results of the
present study and demonstrate the benefits and usefulness
of the tool in primary care settings.
The FibroDetect is available in the form of a four-page
leaflet, a user-friendly format particularly well adapted to
the context of clinical practice where it can be easily ad-
ministered to patients during consultation, after or be-
fore clinical examination. It is completed in less than
10 minutes. Moreover, this tool can be an effective and
standardized method of communication between pa-
tients and doctors by facilitating the dialogue and ex-
change of information. Indeed, the tool can help patients
to explain their symptoms and address their needs, and
help physicians interpret patients’ complaints and recog-
nise fibromyalgia signs at the same time. The use of such
a tool during consultation will not only improve the qual-
ity of care in general practice but will also increase
patients’ and doctors’ satisfaction and improve patients’
self-esteem and well-being [42].
Conclusions
The FibroDetect is a robust tool to screen for potential
fibromyalgia patients among patients who present to
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http://www.hqlo.com/content/12/1/128their PCPs with chronic widespread pain and/or fatigue
as major complaint. The tool can be used as a surrogate
screening classification to ACR criteria for fibromyalgia
in primary care settings. It is validated, and is available
in French, German, and UK English. By comprehensively
assessing the multiple physical and psychological do-
mains and symptoms associated with fibromyalgia, the
FibroDetect screening tool will allow a reduction in the
delay before diagnosis and appropriate referral to spe-
cialists, ensuring access to the best available care. Detec-
tion of fibromyalgia is rendered all the more challenging
because health professionals are often sceptical regarding
the existence of this condition. One advantage of a stan-
dardized detection of fibromyalgia, as proposed by the
FibroDetect screening tool, is to give legitimacy to the
patient’s feedback, which is essential in this controversial
pathological condition.
The measure will be accessible to interested researchers
at the following website: www.pfizerpatientreportedout-
comes.com.
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